JAK2 and essential thrombocythemia: In 2005, several research groups simultaneously published the presence of the somatic mutation p.V617F (JAK2V617F) in the exon 14 of JAK2 in patients with PV (96%), PMF (65%) and ET (55%) [79,80,81,82,83,84].